Blurbs

JonesTrading Sticks to Its Buy Rating for Fusion Pharmaceuticals (FUSN)

JonesTrading analyst Justin Walsh maintained a Buy rating on Fusion Pharmaceuticals (FUSNResearch Report) on November 8 and set a price target of $10.00. The company’s shares opened today at $2.18.

According to TipRanks, Walsh is an analyst with an average return of -31.1% and a 19.05% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, POINT Biopharma Global, and Plus Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fusion Pharmaceuticals with a $10.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $8.73 and a one-year low of $1.98. Currently, Fusion Pharmaceuticals has an average volume of 105.1K.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FUSN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fusion Pharmaceuticals Inc is a clinical stage bio-pharmaceutical company focused on developing alpha therapeutics for curing cancer.

Read More on FUSN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More